Browse RRAS

Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor Cytoplasmic side Note=Inner surface of plasma membrane possibly with attachment requiring acylation of the C-terminal cysteine (By similarity with RAS).
Domain PF00071 Ras family
Function

Regulates the organization of the actin cytoskeleton (PubMed:16537651, PubMed:18270267). With OSPBL3, modulates integrin beta-1 (ITGB1) activity (PubMed:18270267).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0002521 leukocyte differentiation
GO:0007265 Ras protein signal transduction
GO:0010171 body morphogenesis
GO:0030336 negative regulation of cell migration
GO:0040013 negative regulation of locomotion
GO:0043491 protein kinase B signaling
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0051271 negative regulation of cellular component movement
GO:0051896 regulation of protein kinase B signaling
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060325 face morphogenesis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
GO:2000146 negative regulation of cell motility
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0019003 GDP binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04140 Regulation of autophagy
hsa04360 Axon guidance
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-422475: Axon guidance
R-HSA-442742: CREB phosphorylation through the activation of Ras
R-HSA-1266738: Developmental Biology
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-438064: Post NMDA receptor activation events
R-HSA-399955: SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416550: Sema4D mediated inhibition of cell attachment and migration
R-HSA-373755: Semaphorin interactions
R-HSA-112315: Transmission across Chemical Synapses
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RRAS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RRAS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RRAS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9350.0115
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.670.497
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3890.817
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.240.569
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1380.937
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3740.858
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0060.989
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1280.913
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2750.849
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1230.949
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0290.992
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4410.000291
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RRAS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RRAS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RRAS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RRAS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RRAS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RRAS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RRAS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRRAS
Namerelated RAS viral (r-ras) oncogene homolog
Aliases Oncogene RRAS; ras family small GTP binding protein R-Ras; Ras-related protein R-Ras
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RRAS collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.